EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antineoplastic Activity of the Combination Loratadine–Simvastatin–Gefitinib in HPV-Positive Cervical Cancer Cells: In Vitro and In Vivo Studies

Tania Raya-Bahena iD, Rene M Rivera-Escobar, Elisabeth Hernández-Gallegos, Javier E Jiménez-Salazar iD, Pablo Damián-Matsumura iD, Janice García-Quiroz iD, Javier Camacho iD

Cancers · 12.08.2026 · 18 (16) · 2589

DOI: 10.3390/cancers18162589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 12.08.2026. Verfasst von Tania Raya-Bahena und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. IPN 2508, Mexico City 07360, Me…. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaría de Ciencia, Humanidades, Tecnología e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Cervical cancer (CC) is the most clinically significant HPV-associated malignancy. Platinum-based chemotherapies produce drug resistance and serious adverse effects. Drug repurposing and combinations are promising approaches to improve the antitumor response. Here, we evaluated the antineoplastic potential of loratadine and simvastatin alone and in combination with cisplatin and gefitinib in HPV-positive CC cells.

Methods

HeLa and SiHa CC cells were treated with loratadine, simvastatin, cisplatin, gefitinib, or their combinations. Metabolic activity was assessed using the MTT assay to determine drug inhibitory concentrations (IC20, IC50) from concentration–response curves. Apoptosis was assessed by Annexin V-FITC/PI flow cytometry. Clonogenic survival and migratory capacity were evaluated using colony formation and wound-healing assays, respectively. Tumor formation was evaluated in vivo using the chick chorioallantoic membrane model.

Results

Metabolic activity decreased in a concentration-dependent manner following drug treatment in both cell lines. Several combination regimens at IC20 significantly improved reductions in metabolic activity and increases in apoptosis compared with monotherapies or two-drug combinations. Notably, some three-drug combinations, with or without cisplatin, had similar effects to the quadruple regimen. Combination treatments also reduced clonogenic survival and migratory capacity, as well as tumor formation and cancer cell dissemination in vivo.

Conclusions

Drug combinations at relatively low concentrations (IC20) significantly enhanced the anticancer effects on CC cells in in vitro and in vivo settings. These findings support the potential of drug repurposing and combination strategies as promising approaches to decrease adverse side effects while improving therapeutic efficacy for the benefit of CC patients.

Schlagwörter

Stichwörter der Autor:innen

EGFRHPVapoptosiscervical cancercisplatincombination therapydrug repurposinggefitinibloratadinesimvastatin

Autor:innen und Institutionen

  • Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. IPN 2508, Mexico City 07360, Mexico.
  • Department of Biology of Reproduction, Biological Sciences and Health Division (DCBS), Autonomous Metropolitan University (UAM), Mexico City 09310, Mexico.
  • Departamento de Biología de La Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Av. Vasco de Quiroga No. 15, Belisario Domínguez Sección XVI, Tlalpan, Mexico City…

ORCID-Profile: Tania Raya-Bahena, Javier E Jiménez-Salazar, Pablo Damián-Matsumura, Janice García-Quiroz, Javier Camacho

Förderung

  • Secretaría de Ciencia, Humanidades, Tecnología e Innovación

Zitieren

APA

Raya-Bahena, T., Rivera-Escobar, R. M., Hernández-Gallegos, E., Jiménez-Salazar, J. E., Damián-Matsumura, P., García-Quiroz, J., & Camacho, J. (2026). Antineoplastic Activity of the Combination Loratadine–Simvastatin–Gefitinib in HPV-Positive Cervical Cancer Cells: In Vitro and In Vivo Studies. Cancers, 18(16), 2589. https://doi.org/10.3390/cancers18162589

Vancouver

Raya-Bahena T, Rivera-Escobar RM, Hernández-Gallegos E, Jiménez-Salazar JE, Damián-Matsumura P, García-Quiroz J, et al. Antineoplastic Activity of the Combination Loratadine–Simvastatin–Gefitinib in HPV-Positive Cervical Cancer Cells: In Vitro and In Vivo Studies. Cancers. 2026;18(16):2589. doi:10.3390/cancers18162589

BibTeX
@article{RayaBahena2026,
  author = {Raya-Bahena, Tania and Rivera-Escobar, Rene M and Hernández-Gallegos, Elisabeth and Jiménez-Salazar, Javier E and Damián-Matsumura, Pablo and García-Quiroz, Janice and Camacho, Javier},
  title = {Antineoplastic Activity of the Combination Loratadine–Simvastatin–Gefitinib in HPV-Positive Cervical Cancer Cells: In Vitro and In Vivo Studies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2589},
  doi = {10.3390/cancers18162589}
}
Kostenlos starten →